Search or filter publications

Search publications Search

Filter by type:

Filter by publication type

• Book
• Book chapter
• Conference paper
• Journal article
• Patent
• Report
• Software

Filter by year:

Filter from 202620252024202320222021202020192018201720162015201420132012201120102009200820072006 to Filter to 202620252024202320222021202020192018201720162015201420132012201120102009200820072006

---

Search results

• Conference paper
  Routy B, Lenehan J, Daisley B, Messaoudene M, Al K, Richard C, Miller W, Jamal R, Ernst S, Logan D, Belanger K, Martinez-Gili L, Mullish B, Takis P, Samayoa CH, Ninkov M, Parvathy SN, Lambert C, Elkrief A, Lapointe R, Haeryfar M, Burton J, Silverman M, Maleki Set al., 2022,

  614 Microbiome modification with fecal microbiota transplant from healthy donors before anti-PD1 therapy reduces primary resistance to immunotherapy in advanced and metastatic melanoma patients

  , SITC 37th Annual Meeting (SITC 2022) Abstracts, Publisher: BMJ Publishing Group Ltd, Pages: A646-A646
  • Publisher Web Link
  • Cite
• Conference paper
  Lythgoe M, Mullish B, Frampton A, Dama P, Pickford E, Tookman L, Cunnea P, Fotopoulou C, Jeffery I, Fyvie G, Stevenson A, Krell Jet al., 2022,

  ORAL ADMINISTRATION OF MRX0518 IN TREATMENTNAIVE CANCER PATIENTS IS ASSOCIATED WITH COMPOSITIONAL TAXONOMIC AND METABOLOMIC CHANGES INDICATIVE OF ANTI-TUMORIGENIC EFFICACY

  , Publisher: BMJ PUBLISHING GROUP, Pages: A659-A659
  • Author Web Link
  • Cite
• Journal article
  Ianiro G, Mullish BH, Iqbal TH, Terveer EM, Baunwall SMD, Link A, Sokol H, Kupcinskas J, Masucci L, Sanguinetti M, Vehreschild MJGT, Hvas CL, Keller JJ, Gasbarrini A, Kujiper EJ, Cammarota Get al., 2022,

  Minimising the risk of monkeypox virus transmission during faecal microbiota transplantation: recommendations from a European expert panel

  , The Lancet Gastroenterology & Hepatology, Vol: 7, Pages: 979-980, ISSN: 2468-1253
  • Publisher Web Link
  • Cite
• Conference paper
  Mullish BH, Paizs P, Alexander J, Verigos E, McDonald JAK, Ford L, Maneta-Stavrakaki S, Sani M, Roberts LA, Chrysostomou D, Kinross J, Monaghan T, Marchesi JR, Kao D, Takats Zet al., 2022,

  Intestinal microbiota transplant for recurrent Clostridioides difficile infection restores microbial arylsulfatases and sulfatide degradation: a novel mechanism of efficacy?

  , UEG Week 2022, Pages: 823-823
  • Cite
• Journal article
  Forlano R, Sivakumar M, Mullish BH, Manousou Pet al., 2022,

  Gut microbiota—a future therapeutic target for people with non-alcoholic fatty liver disease: a systematic review

  , International Journal of Molecular Sciences, Vol: 23, Pages: 1-13, ISSN: 1422-0067

  Non-alcoholic fatty liver disease (NAFLD) represents an increasing cause of liver disease, affecting one-third of the population worldwide. Despite many medications being in the pipeline to treat the condition, there is still no pharmaceutical agent licensed to treat the disease. As intestinal bacteria play a crucial role in the pathogenesis and progression of liver damage in patients with NAFLD, it has been suggested that manipulating the microbiome may represent a therapeutical option. In this review, we summarise the latest evidence supporting the manipulation of the intestinal microbiome as a potential therapy for treating liver disease in patients with NAFLD.

  • Abstract
  • Publisher Web Link
  • Cite
• Journal article
  Mullish BH, McDonald JAK, Marchesi JR, 2022,

  Mechanisms of efficacy of intestinal microbiota transplant: do not forget the metabolites

  , The Lancet Gastroenterology & Hepatology, Vol: 7, Pages: 594-594, ISSN: 2468-1253
  • Cite
• Journal article
  Ghani R, Mullish BH, Davies FJ, Marchesi JRet al., 2022,

  How to adapt an intestinal microbiota transplantation programme to reduce the risk of invasive multidrug-resistant infection

  , Clinical Microbiology and Infection, Vol: 28, Pages: 502-512, ISSN: 1198-743X
  • Publisher Web Link
  • Cite
• Journal article
  Fromentin S, Forslund SK, Chechi K, Aron-Wisnewsky J, Chakaroun R, Nielsen T, Tremaroli V, Ji B, Prifti E, Myridakis A, Chilloux J, Andrikopoulos P, Fan Y, Olanipekun MT, Alves R, Adiouch S, Bar N, Talmor-Barkan Y, Belda E, Caesar R, Coelho LP, Falony G, Fellahi S, Galan P, Galleron N, Helft G, Hoyles L, Isnard R, Le Chatelier E, Julienne H, Olsson L, Pedersen HK, Pons N, Quinquis B, Rouault C, Roume H, Salem J-E, Schmidt TSB, Vieira-Silva S, Li P, Zimmermann-Kogadeeva M, Lewinter C, Sondertoft NB, Hansen TH, Gauguier D, Gotze JP, Kober L, Kornowski R, Vestergaard H, Hansen T, Zucker J-D, Hercberg S, Letunic I, Backhed F, Oppert J-M, Nielsen J, Raes J, Bork P, Stumvoll M, Segal E, Clement K, Dumas M-E, Ehrlich SD, Pedersen Oet al., 2022,

  Microbiome and metabolome features of the cardiometabolic disease spectrum

  , Nature Medicine, Vol: 28, Pages: 303-+, ISSN: 1078-8956

  Previous microbiome and metabolome analyses exploring non-communicable diseases have paid scant attention to major confounders of study outcomes, such as common, pre-morbid and co-morbid conditions, or polypharmacy. Here, in the context of ischemic heart disease (IHD), we used a study design that recapitulates disease initiation, escalation and response to treatment over time, mirroring a longitudinal study that would otherwise be difficult to perform given the protracted nature of IHD pathogenesis. We recruited 1,241 middle-aged Europeans, including healthy individuals, individuals with dysmetabolic morbidities (obesity and type 2 diabetes) but lacking overt IHD diagnosis and individuals with IHD at three distinct clinical stages—acute coronary syndrome, chronic IHD and IHD with heart failure—and characterized their phenome, gut metagenome and serum and urine metabolome. We found that about 75% of microbiome and metabolome features that distinguish individuals with IHD from healthy individuals after adjustment for effects of medication and lifestyle are present in individuals exhibiting dysmetabolism, suggesting that major alterations of the gut microbiome and metabolome might begin long before clinical onset of IHD. We further categorized microbiome and metabolome signatures related to prodromal dysmetabolism, specific to IHD in general or to each of its three subtypes or related to escalation or de-escalation of IHD. Discriminant analysis based on specific IHD microbiome and metabolome features could better differentiate individuals with IHD from healthy individuals or metabolically matched individuals as compared to the conventional risk markers, pointing to a pathophysiological relevance of these features.

  • Abstract
  • Publisher Web Link
  • Author Web Link
  • Cite
• Journal article
  Talmor-Barkan Y, Bar N, Shaul AA, Shahaf N, Godneva A, Bussi Y, Lotan-Pompan M, Weinberger A, Shechter A, Chezar-Azerrad C, Arow Z, Hammer Y, Chechi K, Forslund SK, Fromentin S, Dumas M-E, Ehrlich SD, Pedersen O, Kornowski R, Segal Eet al., 2022,

  Metabolomic and microbiome profiling reveals personalized risk factors for coronary artery disease

  , NATURE MEDICINE, Vol: 28, Pages: 295-+, ISSN: 1078-8956
  • Cite
  • Citations: 131
• Journal article
  Forlano R, Mullish BH, Roberts LA, Thursz MR, Manousou Pet al., 2022,

  The intestinal barrier and its dysfunction in patients with metabolic diseases and non-alcoholic fatty liver disease

  , International Journal of Molecular Sciences, Vol: 23, ISSN: 1422-0067

  Non-alcoholic fatty liver disease (NAFLD) represents an increasing cause of liver disease worldwide, mirroring the epidemics of obesity and metabolic syndrome. As there are still no licensed medications for treating the disease, there is an ongoing effort to elucidate the pathophysiology and to discover new treatment pathways. An increasing body of evidence has demonstrated a crosstalk between the gut and the liver, which plays a crucial role in the development and progression of liver disease. Among other intestinal factors, gut permeability represents an interesting factor at the interface of the gut–liver axis. In this narrative review, we summarise the evidence from human studies showing the association between increased gut permeability and NAFLD, as well as with type-2 diabetes and obesity. We also discuss the manipulation of the gut permeability as a potential therapeutical target in patients with NAFLD.

  • Abstract
  • Cite

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.